Clearmind Medicine宣布18名酒精使用障碍患者完成CMND-100 I/IIa期临床试验治疗与随访

美股速递
Mar 30

生物科技公司Clearmind Medicine, Inc. (以下简称"Clearmind Medicine") 近日宣布,其针对酒精使用障碍(AUD)的主打候选药物CMND-100正在进行的I/IIa期临床试验取得重要进展。该试验中,首批18名参与者已成功完成了全部治疗方案以及后续的观察随访阶段。

这一里程碑标志着CMND-100在临床开发道路上迈出了坚实的一步,为后续评估该药物的安全性和初步疗效奠定了重要基础。公司表示,将继续推进临床试验的后续环节,以收集更多关键数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10